Latest news

View all

Intellectual Property – February 25, 2026

Salipro Biotech obtains key US patent grant

The new patent secures long term protection for the Salipro platform technologies, extending exclusivity until 2042 and reinforcing the company’s position as a premier partner for drug discovery against challenging drug targets.

Biotech Business – February 25, 2026

Hansa Biopharma’s BLA for imlifidase accepted by the FDA

The company’s Biologics License Application (BLA) for imlifidase has been accepted by the U.S. Food and Drug Administration (FDA).

Financing – February 24, 2026

Oncopeptides carries out a rights issue of approx SEK 200 million

The Board of Directors has resolved to carry out a new share issue of approximately SEK 200 million with preferential rights for the company’s existing shareholders based on the authorization granted by the Annual General Meeting on 22 May 2025.

MedTech Business – February 23, 2026

FDA clears FluoGuide’s IND for FG001 in High-Grade Glioma

The US Food and Drug Administration (FDA) has informed the company that it can proceed with the proposed clinical investigation for FG001.

Agreement – February 23, 2026

Affibody signs Letter of Intent with SHINE Technologies

A Letter of Intent (LOI) has been signed with SHINE Technologies as an additional supplier of non-carrier-added Lutetium-177 (n.c.a. Lu-177).

Biotech Business – February 17, 2026

CubaseBio secures EUR 5.9 million in blended financing

The funding comprises a EUR 2 million non-dilutive grant from the European Innovation Council (EIC) Transition program and EUR 3.9 million in private capital and convertibles from Voima Ventures, Nordic Science Investments (NSI), Illumina Ventures, Almi invest, Life Science Invest and several undisclosed private investors from the genomics technology space.

14 EUR
/month

Read the latest issue of our magazine!

Read the latest issue of our magazine!

  • Beacons of life science: Learn more about Science for Good in the USA, popular science writer Julia Ravanis, and the many dedicated women working to increase female representation in leadership.
  • Cutting-edge science: Learn more about two groundbreaking clinical approaches marking a Nordic entry into the frontline of both diabetes and vision restoration.
  • Global report: Flanders’ economy is anchored by advanced manufacturing, logistics, and a life science sector that consistently performs far above the region’s size.
  • In addition: Stay updated on the latest news within women’s health, health tech, and AI, and find out what it’s like to be a PhD student in the life science industry.
Subscribe now

Opinion & debate

Clinical Trials

Clinical Trials – February 10, 2026

Lundbeck presents real-world data highlighting improvements in migraine

The company has announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness of Vyepti in adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment, at any time point previously.

Clinical Trials – February 2, 2026

SynAct Pharma initiates Phase 2 study in respiratory insufficiency

SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.

Clinical Trials – January 27, 2026

Takeda’s zasocitinib meets primary and secondary endpoints in Phase 3 study

The results showed that approximately 30 percent of patients achieved complete skin clearance (PASI 100) at week 16, and that more than half reached almost complete clearance (PASI 90).

Clinical Trials – January 27, 2026

DexTech Medical’s myeloma study, completed at the end of February

The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease.

Clinical Trials – January 12, 2026

Elicera Therapeutics announces final data from its Phase I/IIa trial

Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.

Clinical Trials – January 9, 2026

Sobi to advance Gamifant in interferon-gamma-driven sepsis

Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

NLS Insight

Global report – May 26, 2025

Doing business in the world’s new life science powerhouse

In a sector long dominated by the US and Europe, Mainland China is now catching up in global pharma and biotechnology. 

Nobel Prize Laureate – December 20, 2018

Frances H. Arnold: Better than Nature herself

Read Chris Tachibana’s exclusive interview with Frances H. Arnold, a Nobel Laureate in Chemistry 2018, and learn more about her bold approaches to optimizing enzymes for society’s benefit.

Careers article – February 15, 2026

Corporate storytelling – Populate your trademark with reality

The method of storytelling has been an excellent way to spread information, knowledge and experiences for centuries.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Job opportunities

View more

PharmaRelations

Business Developer and Consultant Manager Norway

This is a position that combines strategic oversight, business development, and team leadership. The successful candidate will play a pivotal role in shaping our services to our customers.

PharmaRelations

Nordic Head of Quality Assurance (QA)

This is a leadership position that combines strategic oversight, business development, and team leadership. The successful candidate will play a pivotal role in shaping our qualtiy assurance services to our customers.

Otsuka Pharma Scandinavia

Nordic MSL – Immunology

This is a strategically important, scientifically driven role where immunological expertise supports meaningful progress in a collaborative, people-first, and innovative environment.

PharmaRelations

Medical Device QA/RA Consultant

Are you passionate about Quality Assurance and Regulatory Compliance in the Medical Device Device companies? PharmaRelations is expanding its team of expert consultants, and we are looking for a talented QA/RA Medical Device Consultant to join us!

Conaxess Trade

Responsible Person/Sr Manager QA

A high‑impact role where you take ownership of QA across the Nordics and help shape the future of leading self‑care brands. Ready to make your mark?

Confidential

Chief Executive Officer

PharmaRelations, together with the Board of Directors, are seeking an experienced and visionary CEO to lead a rapidly growing Life Science company through its next phase of development and growth. The company is based in southern Sweden.

Explore topics

Upcoming events

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.